Abstract:Objective:This study aims to investigate the effect of the phosphatidylinositol 3-hydroxy kinase(PI3K)-protein kinase B(AKT)-mammalian target of rapamycin(mTOR) pathway on the drug resistance of osteosarcoma cells and its mechanism to provide new ideas for the targeted therapy of osteosarcoma.Methods:MG-63 cells were cultured in vitro, and MG-63 drug-resistant cell lines were established using the repeated administration of 2 μg/mL cisplatin. The high-expression plasmids of miRNA-22 were transfected into MG-63 drug-resistant cell lines to establish MG-63 drug-resistant cell lines with high miRNA-22 expression. MG-63 cells were the control group, and the MG-63 drug-resistant cells were the drug-resistant group. MG-63 frug-resistant cells treated with 2 μg/mL cisplatin and the drug-resistant MG-63 cells transfected with miRNA-22 were the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups, respectively. The cell proliferation was detected using the thiazoline (MTT) assay. The expression levels of PI3K, AKT, and mTOR mRNA were detected using fluorescence quantitative RT-PCR. The protein expressions of PI3K, AKT, pAKT, mTOR, and p-mTOR were detected using the Western blot.Results:(1)The MTT results showed that the absorbance values of the control, drug-resistant, drug-resistant DDP, and drug-resistant miRNA-22+ DDP groups were 1.097±0.039, 1.157±0.065, 0.870±0.014, and 0.737±0.029, respectively. The differences were statistically significant ( F=67.731, P<0.01). Compared with that of the control group, the absorbance of the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups decreased significantly (all P values<0.01). For the drug-resistant, drug-resistant DDP group, and drug-resistant miRNA-22+ DDP group, the absorbance showed a downward trend, and the differences were statistically significant (all P values<0.01). (2)The results of fluorescence quantitative RT-PCR showed that compared with that in the control group, the relative expression of PI3K and AKT in the drug-resistant and the drug-resistant DDP groups increased especially in the drug-resistant group (all P values<0.01). No significant difference was observed between the drug-resistant miRNA-22+ DDP and the control groups (all P values>0.01). The relative expression of mTOR significantly increased in the drug-resistant group and significantly decreased in the drug-resistant DDP and the drug-resistant miRNA-22+ DDP groups (all P values<0.01). The relative expression levels of PI3K, AKT, and mTOR in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were lower than those in the drug-resistant group, and all differences were statistically significant (all P values<0.01). The relative expression levels of PI3K and mTOR in the drug-resistant miRNA-22+ DDP group were lower than those in the drug-resistant DDP group, and the differences were statistically significant (all P values<0.01). (3) The results of Western blot showed that compared with that in the control group, the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant group increased significantly and that the relative expression levels of PI3K and AKT proteins in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were significantly reduced. The differences were statistically significant (all P values<0.01). The pairwise comparison among three groups revealed that the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant DDP and drug-resistant miRNA-22+ DDP groups were significantly lower than those in the drug-resistant group. The relative expression levels of PI3K and AKT proteins in the drug-resistant miRNA-22+ DDP group were significantly lower than those in the drug-resistant DDP group (all P values<0.01). Conclusions:The PI3K-AKT-mTOR pathway was involved in the development of osteosarcoma cells' resistance to cisplatin. miRNA-22 reduced the resistance of osteosarcoma cells to cisplatin by downregulating the expression levels of PI3K, AKT, and mTOR in the PI3K-AKT-mTOR pathway.

Changes of stem cell properties in cisplatin-resistant osteosarcoma cells and its relationship with Notch signaling pathway

Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling.

Doxorubicin induces enrichment of stem-like cells in osteosarcoma by activating Notch signaling

Cisplatin-resistant Osteosarcoma Cells Possess Cancer Stem Cell Properties in a Mouse Model

Cisplatin influences the proliferation of human osteosarcoma 143Bcells by regulating Notch signaling pathway

Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family

Notch signaling pathway regulates osteosarcoma stem cell characteristics by inhibiting Eph pathway

Notch Pathway Inhibition Using DAPT, a Γ‐secretase Inhibitor (GSI), Enhances the Antitumor Effect of Cisplatin in Resistant Osteosarcoma

P-Glycoprotein Overexpression is Associated with Cisplatin Resistance in Human Osteosarcoma

Hedgehog/GLI1 signaling pathway regulates the resistance to cisplatin in human osteosarcoma

SNHG16 Promotes Osteosarcoma Progression and Enhances Cisplatin Resistance by Sponging Mir-16 to Upregulate ATG4B Expression.

Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells

Effect of the PI3K-AKT-mTOR pathway on the drug resistance of osteosarcoma cells and its mechanism

Notch Signaling is Important for Epithelial-Mesenchymal Transition Induced by Low Concentrations of Doxorubicin in Osteosarcoma Cell Lines.

Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma is Associated with Increased Autocrine of IGF1.

Dual Mechanism of Action of Resveratrol in Notch Signaling Pathway Activation in Osteosarcoma

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance

The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair

CXCR1 Knockdown Improves the Sensitivity of Osteosarcoma to Cisplatin

Doxorubicin Inhibits Proliferation Of Osteosarcoma Cells Through Upregulation Of The Notch Signaling Pathway

Activation of Unfolded Protein Response Protects Osteosarcoma Cells from Cisplatin-Induced Apoptosis Through NF-κB Pathway.